Development of a fission yeast-based high-throughput screen to identify chemical regulators of cAMP phosphodiesterases

Journal of Biomolecular Screening

Volumn 13, Issue 1, 2008, Pages 62-71

  Ivey, F Douglas ^a   Wang, Lili ^a   Demirbas, Didem ^a   Allain, Christina ^a   Hoffman, Charles S ^a  

^a BOSTON COLLEGE   (United States)

Author keywords

cAMP; High throughput; Inhibitors; Phosphodiesterase; Schizosaccharomyces pombe

Indexed keywords

CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITOR; ENZYME INHIBITOR; FURANOCOUMARIN IMPERATORIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ENZYME INHIBITION; FUNGAL STRAIN; HIGH THROUGHPUT SCREENING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; YEAST;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; CYCLIC AMP; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; GENES, FUNGAL; GENES, REPORTER; MICE; PHOSPHODIESTERASE INHIBITORS; RECOMBINANT PROTEINS; SCHIZOSACCHAROMYCES;

MAMMALIA; SCHIZOSACCHAROMYCES POMBE; SCHIZOSACCHAROMYCETACEAE;

EID: 37749012052     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107312127     Document Type: Article

References (41)

1. Kamenetsky M., Middelhaufe S., Bank EM, Levin LR, Buck J., Steegborn C.: Molecular details of cAMP generation in mammalian cells: a tale of two systems. J Mol Biol 2006 ; 362 (4). 623-639.
2. Bender AT, Beavo JA: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006 ; 58 (3). 488-520.
3. Lerner A., Epstein PM: Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 2006 ; 393 (pt 1). 21-41.
4. Vasta V., Shimizu-Albergine M., Beavo JA: Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A. Proc Natl Acad Sci U S A 2006 ; 103: 19925-19930.
5. Dyke HJ, Montana JG: Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002 ; 11 (1). 1-13.
6. Boswell-Smith V., Spina D., Page CP: Phosphodiesterase inhibitors. Br J Pharmacol 2006 ; 147 (suppl 1). S252 - S257.
7. O'Donnell JM, Zhang HT: Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004 ; 25 (3). 158-163.
8. Lugnier C.: Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006 ; 109 (3). 366-398.
9. Hebb AL, Robertson HA: Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol 2007 ; 7 (1). 86-92.
10. Hoffman CS, Winston F.: Isolation and characterization of mutants constitutive for expression of the fbp1 gene of Schizosaccharomyces pombe. Genetics 1990 ; 124 (4). 807-816.
11. Hoffman CS: Glucose sensing via the protein kinase A pathway in Schizosaccharomyces pombe. Biochem Soc Trans 2005 ; 33 (pt 1). 257-260.
12. Hoffman CS: Except in every detail: comparing and contrasting G protein signaling in Saccharomyces cerevisiae and Schizosaccharomyces pombe. Eukaryotic Cell 2005 ; 4: 495-503.
13. Degols G., Shiozaki K., Russell P.: Activation and regulation of the Spc1 stress-activated protein kinase in Schizosaccharomyces pombe. Mol Cell Biol 1996 ; 16 (6). 2870-2877.
14. Stettler S., Warbrick E., Prochnik S., Mackie S., Fantes P.: The wis1 signal transduction pathway is required for expression of cAMP- repressed genes in fission yeast. J Cell Sci 1996 ; 109 (pt 7). 1927-1935.
15. Stiefel J., Wang L., Kelly DA, Janoo RTK, Seitz J., Whitehall SK,, et al. Suppressors of an adenylate cyclase deletion in the fission yeast Schizosaccharomyces pombe. Eukaryotic Cell 2004 ; 3 (3). 610-619.
16. Wang L., Griffiths K., Zhang YH, Ivey FD, Hoffman CS: Schizosaccharomyces pombe adenylate cyclase suppressor mutations suggest a role for cAMP phosphodiesterase regulation in feedback control of glucose/cAMP signaling. Genetics 2005 ; 171: 1523-1533.
17. Mochizuki N., Yamamoto M.: Reduction in the intracellular cAMP level triggers initiation of sexual development in fission yeast. Mol Gen Genet 1992 ; 233 (1-2). 17-24.
18. Kim YK, Arai MA, Arai T., Lamenzo JO, Dean EF III, Patterson N.,, et al. Relationship of stereochemical and skeletal diversity of small molecules to cellular measurement space. J Am Chem Soc 2004 ; 126 (45). 14740-14745.
19. Franz AK, Dreyfuss PD, Schreiber SL: Synthesis and cellular profiling of diverse organosilicon small molecules. J Am Chem Soc 2007 ; 129 (5). 1020-1021.
20. Cherry JA, Thompson BE, Pho V.: Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse. Biochim Biophys Acta 2001 ; 1518 (1-2). 27-35.
21. Soderling SH, Bayuga SJ, Beavo JA: Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci U S A 1998 ; 95 (15). 8991-8996.
22. Wu AY, Tang XB, Martinez SE, Ikeda K., Beavo JA: Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem 2004 ; 279 (36). 37928-37938.
23. DeVoti J., Seydoux G., Beach D., McLeod M.: Interaction between ran1+ protein kinase and cAMP dependent protein kinase as negative regulators of fission yeast meiosis. EMBO J 1991 ; 10 (12). 3759-3768.
24. Ivey FD, Hoffman CS Direct activation of fission yeast adenylate cyclase by the Gpa2 Gα of the glucose signaling pathway. Proc Natl Acad Sci U S A 2005 ; 102 (17). 6108-6113.
25. Nocero M., Isshiki T., Yamamoto M., Hoffman CS: Glucose repression of fbp1 transcription of Schizosaccharomyces pombe is partially regulated by adenylate cyclase activation by a G protein α subunit encoded by gpa2 (git8). Genetics 1994 ; 138 (1). 39-45.
26. Welton RM, Hoffman CS: Glucose monitoring in fission yeast via the gpa2 Gα, the git5 Gβ, and the git3 putative glucose receptor. Genetics 2000 ; 156: 513-521.
27. Toone WM, Kuge S., Samuels M., Morgan BA, Toda T., Jones N.: Regulation of the fission yeast transcription factor Pap1 by oxidative stress: requirement for the nuclear export factor Crm1 (Exportin) and the stress-activated MAP kinase Sty1/Spc1. Genes Dev 1998 ; 12 (10). 1453-1463.
28. Toda T., Shimanuki M., Yanagida M.: Fission yeast genes that confer resistance to staurosporine encode an AP-1-like transcription factor and a protein kinase related to the mammalian ERK1/MAP2 and budding yeast FUS3 and KSS1 kinases. Genes Dev 1991 ; 5 (1). 60-73.
29. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4 (2). 67-73.
30. Colicelli J., Nicolette C., Birchmeier C., Rodgers L., Riggs M., Wigler M.: Expression of three mammalian cDNAs that interfere with RAS function in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 1991 ; 88 (7). 2913-2917.
31. Pillai R., Kytle K., Reyes A., Colicelli J.: Use of a yeast expression system for the isolation and analysis of drug-resistant mutants of a mammalian phosphodiesterase. Proc Natl Acad Sci U S A 1993 ; 90 (24). 11970-11974.
32. Atienza JM, Colicelli J.: Yeast model system for study of mammalian phosphodiesterases. Methods 1998 ;14(1): 35-42.
33. Wachtel H.: Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3′, 5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology (Berl) 1982 ; 77 (4). 309-316.
34. Wachtel H.: Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 1983 ; 22 (3). 267-272.
35. Lamontagne S., Meadows E., Luk P., Normandin D., Muise E., Boulet L.,, et al. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res 2001 ; 920 (1-2). 84-96.
36. Miro X., Perez-Torres S., Puigdomenech P., Palacios JM, Mengod G.: Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse 2002 ; 45 (4). 259-269.
37. Peluso MR: Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver. Exp Biol Med (Maywood) 2006 ; 231 (8). 1287-1299.
38. Duarte J., Lugnier C., Torres AI, Perez-Vizcaino F., Zarzuelo A., Tamargo J.: Effects of visnagin on cyclic nucleotide phosphodiesterases and their role in its inhibitory effects on vascular smooth muscle contraction. Gen Pharmacol 1999 ; 32 (1). 71-74.
39. Bovalini L., Lusini P., Simoni S., Vedaldi D., Andreassi L., Dall'Acqua F.,, et al. Inhibition of cAMP phosphodiesterase by some phototherapeutic agents. Z Naturforsch C 1987 ; 42 (7-8). 1009-1010.
40. Sancho R., Marquez N., Gomez-Gonzalo M., Calzado MA, Bettoni G., Coiras MT,, et al. Imperatorin inhibits HIV-1 replication through an Sp1-dependent pathway. J Biol Chem 2004 ; 279 (36). 37349-37359.
41. Angel JB, Saget BM, Walsh SP, Greten TF, Dinarello CA, Skolnik PR,, et al. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. AIDS 1995 ; 9 (10). 1137-1144.